{
    "CSUI": {
        "short_name": "CANNABIS SUISSE CORP",
        "long_name": "Cannabis Suisse Corp.",
        "summary": "Cannabis Suisse Corp. engages in the cultivation and distribution of recreational tobacco products and medical CBD oils in Switzerland. The company sells its products through a distribution network of retailers and online shops under the Swiss4Life retail brand. The company was formerly known as Geant Corp. and changed its name to Cannabis Suisse Corp. in February 2019. Cannabis Suisse Corp. was incorporated in 2016 and is based in Dietikon, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "state": null,
        "city": "Dietikon",
        "zipcode": "8953",
        "website": "http://www.cannabissuissecorp.com",
        "market_cap": "Small Cap"
    },
    "ELN.F": {
        "short_name": "ELANIX BIOTECHN.AG",
        "long_name": "Elanix Biotechnologies AG",
        "summary": "Elanix Biotechnologies AG, a tissue regeneration company, develops and commercializes products for acute wound care, dermatological, and gynecological applications, and provides cell technology services. It also owns cell banks containing various quantities of cells. The company was founded in 1966 and is headquartered in Epalinges, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "state": null,
        "city": "Epalinges",
        "zipcode": "1066",
        "website": "http://www.elanixbiotechnologies.ch",
        "market_cap": "Small Cap"
    },
    "G2AB.F": {
        "short_name": "VIFOR PHARMA UNSP.ADR/0,2",
        "long_name": "Vifor Pharma AG",
        "summary": "Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "state": null,
        "city": "Sankt Gallen",
        "zipcode": "9014",
        "website": "http://www.viforpharma.com",
        "market_cap": "Mid Cap"
    },
    "GNHAF": {
        "short_name": "VIFOR PHARMA AG",
        "long_name": "Vifor Pharma AG",
        "summary": "Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "state": null,
        "city": "Sankt Gallen",
        "zipcode": "9014",
        "website": "http://www.viforpharma.com",
        "market_cap": "Mid Cap"
    },
    "GNHAY": {
        "short_name": "VIFOR PHARMA AG",
        "long_name": "Vifor Pharma AG",
        "summary": "Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "state": null,
        "city": "Sankt Gallen",
        "zipcode": "9014",
        "website": "http://www.viforpharma.com",
        "market_cap": "Mid Cap"
    },
    "PPGN.SW": {
        "short_name": "POLYPEPTIDE N",
        "long_name": "PolyPeptide Group AG",
        "summary": "PolyPeptide Group AG operates as a pharmaceutical products contract development and manufacturing organization worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. The company provides GMP compliance and inspection, custom research and development, pre-GMP development, production, quality assurance, quality control, and regulatory support services. It also manufactures and sells peptide-based generics, cosmetic peptides, and individualized peptide therapeutics. The company was founded in 1996 and is based in Zug, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "state": null,
        "city": "Zug",
        "zipcode": "6300",
        "website": "http://www.polypeptide.com",
        "market_cap": null
    },
    "SESI": {
        "short_name": "SES SOLAR INC",
        "long_name": "SES Solar Inc.",
        "summary": "SES Solar Inc. develops and delivers products in the field of photovoltaic energy in Switzerland. The company offers a range of photovoltaic products, such as solar tiles that comprise standard panels primarily for urban or rural areas, and flat or sloped roofs; and custom/architecturally integrated panels made of glass/glass tedlar, which are used for glazing, light admitting apertures in industrial and residential buildings, as well as for veranda roofs. It also handles project management services from design to completion, as well as provides monitoring (supervision), maintenance, and operation services. The company was founded in 2001 and is based in Plan-les-Ouates, Switzerland. As of November 23, 2010, SES Solar Inc. operates as a subsidiary of Flannel Management S\u00c3\u00a0rl.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "state": null,
        "city": "Plan-les-Ouates",
        "zipcode": "1228",
        "website": "http://www.societe-energie-solaire.com",
        "market_cap": "Small Cap"
    },
    "SFZN.SW": {
        "short_name": "SIEGFRIED N",
        "long_name": "Siegfried Holding AG",
        "summary": "Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling liquid dosage forms. It offers contract development and manufacturing services, including process and chemical development, analytical development, pilot manufacturing and scale up, and commercial manufacturing. The company also provides APIs and controlled substances focusing on anesthetics, pain/addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "state": null,
        "city": "Zofingen",
        "zipcode": "4800",
        "website": "http://www.siegfried.ch",
        "market_cap": "Mid Cap"
    },
    "VIFN.SW": {
        "short_name": "VIFOR N",
        "long_name": "Vifor Pharma AG",
        "summary": "Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "state": null,
        "city": "Sankt Gallen",
        "zipcode": "9014",
        "website": "http://www.viforpharma.com",
        "market_cap": "Mid Cap"
    }
}